--Germany could consider banning the export of Novo Nordisk's Ozempic drug amid a shortage of the medication for diabetes patients, the head of the country's federal institute for drugs and medical devices tells Der Spiegel in an interview. Ozempic is approved for diabetes treatment but is also being used "off-label" as a weight-loss medication.

--The institute's president, Karl Broich, says that Ozempic is cheaper in Germany than in some other countries and that some supply is ending up in other European countries or the U.S., the magazine reports.

--"We need the drug for the treatment of diabetes patients and not as a life-style medication," he says, adding that if current measures don't work, a ban could be considered, according to Der Spiegel.

Full story in German: https://tinyurl.com/2bzrm5by

Write to Kim Richters at kim.richters@wsj.com

(END) Dow Jones Newswires

November 15, 2023 09:35 ET (14:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Novo Nordisk (NYSE:NVO)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Novo Nordisk
Grafico Azioni Novo Nordisk (NYSE:NVO)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Novo Nordisk